Bevacizumab plus iparomlimab/tuvonralimab with hepatic artery infusion chemotherapy followed by stereotactic body radiotherapy in patients with BCLC stage C hepatocellular carcinoma with thrombus and/or extrahepatic oligometastases (BITS-TO-HCC): study protocol of a prospective, single-center, single-arm, phase II study Authors: Yuxin Liu, Haohua Wang, Kunli Zhu, Shumei Jiang, Fang Shi, Rui Feng, Xue Dou, Lei Xu, Zhe Gong, Shuai Wang, Chen Wang, Po Wang, Xiang Zhang, Jinbo Yue Published: 2026 ABSTRACT AbstractBackground:First-line immunotherapy-based combinations have improved outcomes in advanced hepatocellular carcinoma (HCC), but many patients with Barcelona Clinic Liver Cancer (BCLC) stage C HCC with portal vein tumor thrombus (PVTT) and/or extrahepatic oligometastases remain difficult to treat and often unresectable.Objectives:To characterize the safety, feasibility, and efficacy of a sequential strategy combining hepatic artery infusion chemotherapy with infusional fluorouracil, leucovorin, and oxaliplatin (HAIC-FO), iparomlimab/tuvonralimab plus bevacizumab, followed by stereotactic body radiotherapy (SBRT), in patients with BCLC stage C HCC with PVTT and/or extrahepatic oligometastases.Design:The BITS-TO-HCC study is a prospective, single-center, single-arm, phase II trial.Methods and analysis:Patients with BCLC stage C HCC complicated by PVTT and/or extrahepatic oligometastases and Child–Pugh class A liver function will be enrolled. On day 1 of each cycle, patients will receive HAIC-FO followed by bevacizumab plus iparomlimab/tuvonralimab after protocol-defined laboratory reassessment. HAIC-FO will be delivered for up to four cycles. After cycle 4, patients without progressive disease will receive protocol-specified SBRT (25–40 Gy in 5 fractions). Patients with radiographic complete response or no residual SBRT-amenable lesion will continue systemic therapy and follow-up. The primary endpoint is progression-free survival. Secondary endpoints include objective response rate, disease control rate, overall survival, local control rate, safety, and quality of life.Ethics:The final protocol was approved by the Ethics Committee of the Affiliated Cancer Hospital of Shandong First Medical University.Discussion:This trial will prospectively evaluate whether a sequential strategy combining HAIC with bevacizumab plus iparomlimab/tuvonralimab followed by SBRT can provide a surgery-sparing, ablative locoregional–systemic pathway for this high-risk population, potentially enhancing efficacy while maintaining an acceptable safety profile.Trial registration: This study is registered on ClinicalTrials.gov Identifier: NCT07062055 (July 14, 2025).Keywords: dual immune checkpoint inhibitors, extrahepatic oligometastases, hepatic artery infusion chemotherapy, hepatocellular carcinoma, portal vein tumor thrombus, stereotactic body radiotherapy Background In recent years, first-line systemic treatment of advanced hepatocellular carcinoma (HCC) has shifted toward immunotherapy-based combinations, particularly regimens pairing immune checkpoint inhibitors (ICIs) with vascular endothelial growth factor (VEGF) or VEGF receptor (VEGFR)–targeted antiangiogenic agents, which have become the preferred options in major clinical guidelines.1–4 Nevertheless, a substantial proportion of patients with Barcelona Clinic Liver Cancer (BCLC) stage C disease complicated by portal vein tumor thrombus (PVTT) and/or extrahepatic oligometastases remain ineligible for resection despite conversion-oriented systemic or locoregional therapy.5,6 Even when hepatectomy is attempted in this subset, candidates are highly selected, and the overall benefit appears limited.7,8 Accordingly, major contemporary guidelines adopt a cautious stance on resection in the presence of PVTT, which remains controversial in some respects.4,9,10 In parallel, recent phase III trials evaluating transarterial chemoembolization (TACE) in combination with immunotherapy and anti-VEGF agents have supported the emergence of a locoregional–systemic treatment paradigm for unresectable, non-metastatic HCC.9,11,12 However, patients with BCLC stage C HCC with PVTT and/or extrahepatic oligometastases were generally under-represented or excluded, leaving the applicability of these regimens to this population uncertain. By contrast, stereotactic body radiotherapy (SBRT) delivered with ablative intent can achieve high local control under stringent dose–volume constraints. 13 Furthermore, radiotherapy (RT) may induce immunogenic cell death and reshape the tumor microenvironment, thereby amplifying systemic immune responses and providing a biological rationale for combination with ICIs and anti-VEGF therapy.14–16 Iparomlimab/tuvonralimab, a novel bispecific antibody designed to target both programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte–associated protein 4 (CTLA-4), offers a promising approach to augment T-cell activation and strengthen antitumor immunity beyond what is achievable with single-agent ICIs. 17 When combined with bevacizumab, which blocks VEGF signaling to normalize tumor vasculature, improves the tumor microenvironment, and promotes immune-cell infiltration, this dual strategy could significantly enhance treatment efficacy.18–20 Hepatic artery infusion chemotherapy (HAIC) concentrates cytotoxic exposure within the liver and induces rapid cytoreduction, facilitating downstaging in advanced HCC.21,22 For the HAIC component, we selected an FOHAIC-1–based regimen of HAIC with infusional fluorouracil, leucovorin, and oxaliplatin (HAIC-FO) because it is among the best-validated HAIC backbones in advanced HCC and significantly improved overall survival (OS) versus sorafenib in the randomized phase III FOHAIC-1 trial. 22 This oxaliplatin–fluorouracil–leucovorin HAIC backbone has also been explored in combination studies with immunotherapy and antiangiogenic therapy, supporting its feasibility within multimodal treatment strategies.23,24 Among patients who remain ineligible for resection despite modern conversion strategies, HAIC-mediated debulking can help render intrahepatic disease dosimetrically amenable to local ablation with SBRT. 22 Building on this rationale, we hypothesize that a sequential regimen combining dual ICIs (iparomlimab/tuvonralimab) and bevacizumab with HAIC, followed by consolidative SBRT, will act synergistically to improve progression-free survival (PFS) in patients with BCLC stage C HCC complicated by PVTT and/or extrahepatic oligometastases, while maintaining an acceptable safety profile. Methods/design Aim and study design The BITS-TO-HCC study is a prospective, single-center, single-arm, phase II clinical trial conducted at the Affiliated Cancer Hospital of Shandong First Medical University. A total of 54 eligible patients will receive HAIC-FO on day 1 (for up to four cycles), followed sequentially by bevacizumab plus iparomlimab/tuvonralimab. After completion of cycle 4, patients without progressive disease (PD) will proceed to protocol-specified SBRT for residual SBRT-amenable lesions, with selective or staged treatment permitted when all residual sites cannot be safely treated within protocol-defined dose–volume constraints. Patients who achieve radiographic complete response (CR), or otherwise have no residual viable lesion amenable to SBRT on contrast-enhanced computed tomography (CT)/MRI, will continue protocol-specified systemic therapy and follow-up. The overall study design, including the enrollment, treatment, and follow-up periods, is shown in Figure 1. The reporting of this study conforms to SPIRIT guidelines 25 (see Supplemental Appendix 1). Study flow. (a) Study schema. (b) Systemic therapy flowchart and cycle timeline. CR, complete response; HAIC, hepatic artery infusion chemotherapy; PD, progressive disease; PR, partial response; PVTT, portal vein tumor thrombus; SBRT, stereotactic body radiotherapy; SD, stable disease. Primary endpoints and definition PFS, defined as the time from the date of first study treatment to disease progression per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1), or death from any cause. PFS, defined as the time from the date of first study treatment to disease progression per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1), or death from any cause. Secondary endpoints and definitions OS, defined as the time from enrollment to death from any cause. OS, defined as the time from enrollment to death from any cause. Objective response rate (ORR), defined as the proportion of patients achieving a best overall response of CR or PR per RECIST 1.1. Objective response rate (ORR), defined as the proportion of patients achieving a best overall response of CR or PR per RECIST 1.1. Disease control rate (DCR), defined as the proportion of patients achieving a best overall response of CR, PR, or stable disease (SD) per RECIST 1.1. Disease control rate (DCR), defined as the proportion of patients achieving a best overall response of CR, PR, or stable disease (SD) per RECIST 1.1. Local control rate (LCR), defined as the proportion of treated lesions without in-field local progression within the irradiated/target volume at prespecified time points (e.g., 6 and 12 months) per RECIST 1.1. Local control rate (LCR), defined as the proportion of treated lesions without in-field local progression within the irradiated/target volume at prespecified time points (e.g., 6 and 12 months) per RECIST 1.1. Safety and tolerability graded by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Safety and tolerability graded by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Health-related quality of life (the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) and QLQ-HCC18). Health-related quality of life (the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) and QLQ-HCC18). Exploratory endpoints and definitions Pretreatment tissue-based biomarkers, including PD-L1 expression and tumor mutational burden (TMB). Pretreatment tissue-based biomarkers, including PD-L1 expression and tumor mutational burden (TMB). Longitudinal peripheral immune profiling, including circulating lymphocyte subsets and prespecified checkpoint-related phenotypes in peripheral immune cells. Longitudinal peripheral immune profiling, including circulating lymphocyte subsets and prespecified checkpoint-related phenotypes in peripheral immune cells. Circulating biomarkers, including serum/plasma immune- and angiogenesis-related soluble factors and circulating tumor DNA (ctDNA) dynamics. Circulating biomarkers, including serum/plasma immune- and angiogenesis-related soluble factors and circulating tumor DNA (ctDNA) dynamics. Exploratory biomarker–outcome associations, including associations of baseline biomarker status and on-treatment biomarker changes with ORR, DCR, LCR, PFS, and OS. Exploratory biomarker–outcome associations, including associations of baseline biomarker status and on-treatment biomarker changes with ORR, DCR, LCR, PFS, and OS. Descriptive/exploratory analyses of efficacy trends according to baseline disease pattern, including the presence of PVTT and/or extrahepatic oligometastases. Descriptive/exploratory analyses of efficacy trends according to baseline disease pattern, including the presence of PVTT and/or extrahepatic oligometastases. Inclusion criteria 1. Unresectable HCC, BCLC Stage C according to the BCLC strategy—2026 update, with staging established via biopsy pathology and/or clinical diagnosis. 4 1. Unresectable HCC, BCLC Stage C according to the BCLC strategy—2026 update, with staging established via biopsy pathology and/or clinical diagnosis. 4 2. Child–Pugh class A without clinically significant hepatic decompensation; Eastern Cooperative Oncology Group (ECOG) performance status 0–1. 2. Child–Pugh class A without clinically significant hepatic decompensation; Eastern Cooperative Oncology Group (ECOG) performance status 0–1. 3. Metastatic burden and SBRT eligibility. 3. Metastatic burden and SBRT eligibility. ● Extrahepatic oligometastatic disease defined as ⩽3 involved organs with ⩽5 total metastatic lesions. ● Extrahepatic oligometastatic disease defined as ⩽3 involved organs with ⩽5 total metastatic lesions. ● All intended intrahepatic and/or extrahepatic SBRT targets must satisfy protocol-specified target-coverage, liver reserve, and organs at risk (OAR) constraints within a composite 5-fraction plan. ● All intended intrahepatic and/or extrahepatic SBRT targets must satisfy protocol-specified target-coverage, liver reserve, and organs at risk (OAR) constraints within a composite 5-fraction plan. 4. Prognosis and measurable disease 4. Prognosis and measurable disease ● Life expectancy ⩾3 months. ● Life expectancy ⩾3 months. ● ⩾1 measurable lesion (per RECIST 1.1): ● ⩾1 measurable lesion (per RECIST 1.1): ● Tumor: ⩾10 mm (CT long axis). ● Tumor: ⩾10 mm (CT long axis). ● Lymph node: ⩾15 mm (CT short axis). ● Lymph node: ⩾15 mm (CT short axis). 5. Prior therapy 5. Prior therapy ● Prior locoregional therapy is permitted, including radiofrequency ablation (RFA), TACE, or HAIC, provided that: ● Prior locoregional therapy is permitted, including radiofrequency ablation (RFA), TACE, or HAIC, provided that: ● Documented radiographic progression or intolerance after the prior therapy. ● Documented radiographic progression or intolerance after the prior therapy. ● Washout ⩾28 days. ● Washout ⩾28 days. ● Treatment-related toxicities recovered to ⩽Grade 1 (alopecia and peripheral neuropathy ⩽Grade 2 allowed). ● Treatment-related toxicities recovered to ⩽Grade 1 (alopecia and peripheral neuropathy ⩽Grade 2 allowed). 6. Laboratory and virologic requirements 6. Laboratory and virologic requirements ● Absolute neutrophil count ⩾1.5 × 109/L, platelet count ⩾75 × 109/L, and hemoglobin ⩾90 g/L. ● Absolute neutrophil count ⩾1.5 × 109/L, platelet count ⩾75 × 109/L, and hemoglobin ⩾90 g/L. ● Aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase (ALP) ⩽5 × upper limit of normal (ULN); total bilirubin (TBiL) ⩽3 × ULN; serum albumin ⩾28 g/L. ● Aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase (ALP) ⩽5 × upper limit of normal (ULN); total bilirubin (TBiL) ⩽3 × ULN; serum albumin ⩾28 g/L. ● Serum creatinine ⩽1.5 × ULN or creatinine clearance ⩾50 mL/min. ● Serum creatinine ⩽1.5 × ULN or creatinine clearance ⩾50 mL/min. ● Urine dipstick protein <2+; if baseline dipstick proteinuria is ⩾2+, 24-h urinary protein must be <1 g. ● Urine dipstick protein <2+; if baseline dipstick proteinuria is ⩾2+, 24-h urinary protein must be <1 g. ● International normalized ratio and activated partial thromboplastin time ⩽1.5 × ULN. ● International normalized ratio and activated partial thromboplastin time ⩽1.5 × ULN. ● For patients with active HBV or HCV infection: ongoing antiviral therapy is required during the study; before study treatment, HBV DNA must be <2000 IU/mL (or <104 copies/mL) and HCV RNA <103 copies/mL. ● For patients with active HBV or HCV infection: ongoing antiviral therapy is required during the study; before study treatment, HBV DNA must be <2000 IU/mL (or <104 copies/mL) and HCV RNA <103 copies/mL. Exclusion criteria 1. Histopathological exclusions 1. Histopathological exclusions ● Mixed HCC subtypes: Fibrolamellar HCC or sarcomatoid HCC or cholangiocarcinoma components. ● Mixed HCC subtypes: Fibrolamellar HCC or sarcomatoid HCC or cholangiocarcinoma components. 2. Curative local therapy candidacy 2. Curative local therapy candidacy ● Current candidacy for resection, liver transplant, or RFA. ● Current candidacy for resection, liver transplant, or RFA. 3. RT infeasibility 3. RT infeasibility ● Prior radioembolization. ● Prior radioembolization. ● Single liver tumor ⩾15 cm or total intrahepatic tumor diameter ⩾20 cm. ● Single liver tumor ⩾15 cm or total intrahepatic tumor diameter ⩾20 cm. ● More than 5 discrete intrahepatic parenchymal foci are present. ● More than 5 discrete intrahepatic parenchymal foci are present. ● Direct tumor extension into the stomach, duodenum, small bowel, or large bowel. ● Direct tumor extension into the stomach, duodenum, small bowel, or large bowel. ● Measurable common or main-branch biliary duct involvement. ● Measurable common or main-branch biliary duct involvement. ● Prior liver RT that would result in excessive overlap with the planned treatment fields. ● Prior liver RT that would result in excessive overlap with the planned treatment fields. 4. Prior systemic therapies 4. Prior systemic therapies ● Received targeted-immunotherapy for HCC (e.g., PD-(L)1 inhibitors + tyrosine kinase inhibitors (TKIs)). ● Received targeted-immunotherapy for HCC (e.g., PD-(L)1 inhibitors + tyrosine kinase inhibitors (TKIs)). ● Prior immunotherapy: anti-PD-(L)1/CTLA-4 or chimeric antigen receptor T-cell therapy. ● Prior immunotherapy: anti-PD-(L)1/CTLA-4 or chimeric antigen receptor T-cell therapy. 5. Hemorrhage/portal hypertension and hepatic decompensation risk 5. Hemorrhage/portal hypertension and hepatic decompensation risk ● Variceal bleeding within 6 months. ● Variceal bleeding within 6 months. ● Untreated or high-risk esophagogastric varices (e.g., grade ⩾2 on endoscopy within 3 months) or other clinical evidence of portal hypertension with high bleeding risk per investigator. ● Untreated or high-risk esophagogastric varices (e.g., grade ⩾2 on endoscopy within 3 months) or other clinical evidence of portal hypertension with high bleeding risk per investigator. ● Moderate or severe ascites. ● Moderate or severe ascites. ● History of or active hepatic encephalopathy. ● History of or active hepatic encephalopathy. ● History of hemoptysis (⩾2.5 mL of bright red blood per episode) within 28 days before study treatment. ● History of hemoptysis (⩾2.5 mL of bright red blood per episode) within 28 days before study treatment. ● Evidence of bleeding diathesis or significant coagulopathy. ● Evidence of bleeding diathesis or significant coagulopathy. ● Current or recent (within 10 days before study treatment) use of aspirin (⩾325 mg/day), dipyridamole, ticlopidine, clopidogrel, cilostazol, or therapeutic-dose oral/parenteral anticoagulants or thrombolytic agents. ● Current or recent (within 10 days before study treatment) use of aspirin (⩾325 mg/day), dipyridamole, ticlopidine, clopidogrel, cilostazol, or therapeutic-dose oral/parenteral anticoagulants or thrombolytic agents. 6. Allergy to any component of iparomlimab/tuvonralimab or bevacizumab. 6. Allergy to any component of iparomlimab/tuvonralimab or bevacizumab. 7. Comorbidities 7. Comorbidities ● Active autoimmune disease or a history of autoimmune or inflammatory disease that may relapse; exceptions include hypothyroidism controlled with hormone replacement only, controlled celiac disease, and skin disorders not requiring systemic treatment (e.g., vitiligo, psoriasis, or alopecia). ● Active autoimmune disease or a history of autoimmune or inflammatory disease that may relapse; exceptions include hypothyroidism controlled with hormone replacement only, controlled celiac disease, and skin disorders not requiring systemic treatment (e.g., vitiligo, psoriasis, or alopecia). ● Any condition requiring systemic corticosteroids (>10 mg/day prednisone or equivalent) or other immunosuppressive medication within 14 days before study treatment. ● Any condition requiring systemic corticosteroids (>10 mg/day prednisone or equivalent) or other immunosuppressive medication within 14 days before study treatment. ● Active or uncontrolled infection, including tuberculosis, or known HIV infection. ● Active or uncontrolled infection, including tuberculosis, or known HIV infection. ● Prior allogeneic stem cell transplantation or organ transplantation. ● Prior allogeneic stem cell transplantation or organ transplantation. ● Inadequately controlled hypertension, defined as systolic blood pressure ⩾150 mmHg and/or diastolic blood pressure >90 mmHg despite optimal medical management, or a history of hypertensive crisis or hypertensive encephalopathy. ● Inadequately controlled hypertension, defined as systolic blood pressure ⩾150 mmHg and/or diastolic blood pressure >90 mmHg despite optimal medical management, or a history of hypertensive crisis or hypertensive encephalopathy. ● History within 6 months before study treatment of myocardial infarction, unstable angina, symptomatic heart failure (New York Heart Association class ⩾II), cerebrovascular accident, transient ischemic attack, pulmonary embolism, deep vein thrombosis, or other serious thromboembolic events. ● History within 6 months before study treatment of myocardial infarction, unstable angina, symptomatic heart failure (New York Heart Association class ⩾II), cerebrovascular accident, transient ischemic attack, pulmonary embolism, deep vein thrombosis, or other serious thromboembolic events. ● Major surgical procedure within 28 days before study treatment, or serious, non-healing or dehiscing wound, active ulcer, or untreated bone fracture. ● Major surgical procedure within 28 days before study treatment, or serious, non-healing or dehiscing wound, active ulcer, or untreated bone fracture. ● History within 6 months before study treatment of gastrointestinal (GI) perforation, abdominal or tracheoesophageal fistula, or intra-abdominal abscess. ● History within 6 months before study treatment of gastrointestinal (GI) perforation, abdominal or tracheoesophageal fistula, or intra-abdominal abscess. Study procedures Safety run-in phase and ongoing safety monitoring To ensure early safety and feasibility before subsequent accrual expansion, the first six consecutively enrolled patients will constitute a safety/feasibility cohort. The dose-limiting toxicity (DLT) observation window will extend from the first study treatment to 60 days after completion of SBRT, or to 60 days after the last protocol treatment in patients who do not proceed to SBRT, whichever occurs later. After all six patients have completed the protocol-defined DLT observation window, a formal multidisciplinary safety review will be conducted by the Safety Review Committee/Data and Safety Monitoring Board (SRC/DSMB). If ⩽1 of 6 patients experiences protocol-defined DLT and no unacceptable toxicity is observed, subsequent accrual will proceed. If ⩾2 of 6 patients experience DLT, accrual will be suspended pending SRC/DSMB review and consideration of protocol modification, including dose and/or procedural adjustments, before further enrollment resumes. Beyond the initial safety run-in phase, cumulative safety will be monitored prospectively throughout the study. If the cumulative rate of treatment-related grade 4–5 non-hematologic adverse events (AEs) among all treated patients exceeds 20%, enrollment will be suspended and reviewed by the SRC/DSMB. Any treatment-related grade 5 AE will trigger immediate safety review. Screening and baseline assessments After written informed consent, baseline assessments will include medical history, vital signs, physical examination, ECOG performance status, hematology and serum biochemistry; viral hepatitis screening (HBV and HCV, with nucleic acid testing as clinically indicated); screening for HIV and Epstein-Barr virus; urinalysis; electrocardiogram; and a urine pregnancy test for women of childbearing potential. Baseline imaging (contrast-enhanced CT or MRI of the chest/abdomen/pelvis, brain MRI, and whole-body bone scintigraphy) will be completed within 28 days before initiation of study treatment. Positron emission tomography (PET)/CT may be used as an alternative screening modality; if abnormal findings are detected, additional diagnostic CT or MRI will be performed to facilitate subsequent response evaluation. The imaging modalities employed at baseline should remain consistent throughout all follow-up assessments. HAIC and systemic therapy On day 1 of each cycle, HAIC using the HAIC-FO regimen will be initiated via a hepatic arterial catheter or pump and completed over 2–3 days, as follows: oxaliplatin 130 mg/m2, leucovorin 200 mg/m2, fluorouracil 400 mg/m2 as a bolus, followed by fluorouracil 2400 mg/m2 by continuous infusion over 46 h. 22 A post-HAIC hepatic laboratory reassessment will be performed approximately 7 (±2) days after HAIC initiation. Subsequently, if no clinically significant hepatic decompensation is present and protocol-defined hepatic, hematologic, renal, and coagulation criteria are met, patients will then receive bevacizumab 15 mg/kg followed by iparomlimab/tuvonralimab 7.5 mg/kg. HAIC-FO may be administered every 3 weeks for up to four cycles. Systemic therapy may continue every 3 weeks until PD or unacceptable toxicity, with a maximum on-study treatment duration of 2 years. Imaging assessment and SBRT eligibility To evaluate treatment efficacy and monitor disease status, an interim imaging assessment will be performed after two treatment cycles using contrast-enhanced CT or MRI. A formal imaging assessment for SBRT candidacy will be performed after completion of cycle 4. Patients without PD who have radiographically identifiable residual viable lesions amenable to SBRT will proceed to SBRT according to protocol-defined criteria. SBRT is intended as protocol-directed consolidative local treatment for residual radiographically viable lesions after completion of cycle 4. For patients with residual PVTT and/or intrahepatic disease, residual intrahepatic lesions designated for SBRT, including the primary hepatic lesion if persistent and residual PVTT, will be treated whenever they can be safely encompassed within a protocol-compliant composite 5-fraction plan. Treatment of all residual lesions is required only when target-coverage, liver reserve, and organ-at-risk constraints can be satisfied. If irradiation of all residual intrahepatic and extrahepatic sites is not feasible because of cumulative dose–volume limitations or organ-at-risk constraints, selective or staged SBRT is permitted after multidisciplinary review. In patients with extrahepatic oligometastatic disease, priority will be given to lesions causing or threatening clinically significant morbidity, including compression, obstruction, or pain. Lesions deferred from SBRT will continue to be managed with protocol-specified systemic therapy and close imaging surveillance. To ensure safety, bevacizumab will be withheld for at least one cycle and, if clinically indicated, for up to two cycles before SBRT. SBRT simulation and planning CT will be scheduled within 7–14 days after the qualifying imaging assessment, and SBRT will be initiated within 14 days thereafter. A representative case illustrating longitudinal MRI changes during HAIC followed by immune-targeted systemic therapy, culminating in eligibility for consolidative SBRT, is shown in Figure 2. Serial contrast-enhanced liver MRI demonstrating treatment response to HAIC followed by immune-targeted systemic therapy. Columns show arterial, portal venous, and delayed phases, and T2-weighted fat-suppressed images. (a) Baseline images showing a hepatic mass with prominent arterial enhancement. (b) After three cycles of combined systemic therapy and HAIC, the lesion shows a marked reduction in size and arterial enhancement. (c) After four cycles (completion of induction and last HAIC), further cytoreduction is evident, fulfilling protocol criteria to proceed with consolidative SBRT. HAIC, hepatic artery infusion chemotherapy. Patients who achieve radiographic CR, or otherwise have no residual viable lesion amenable to SBRT on contrast-enhanced CT/MRI, will continue protocol-specified systemic therapy and follow-up. Patients with PD will discontinue protocol treatment and receive subsequent therapy as determined by the multidisciplinary team. SBRT planning and delivery Simulation will be performed using contrast-enhanced planning CT, preferably liver-protocol CT for liver-directed targets, with protocol-specified immobilization and respiratory motion management procedures, including four-dimensional CT, breath-hold, respiratory gating, or abdominal compression, as appropriate. The qualifying contrast-enhanced CT and/or MRI will be fused with the planning dataset for target delineation. Gross tumor volume (GTV) will encompass all residual radiographically viable lesions designated for SBRT, including residual PVTT and/or extrahepatic oligometastatic lesions; if the primary hepatic lesion persists, it will also be included. For hepatic parenchymal lesions, clinical target volume (CTV) will generally be equivalent to GTV without expansion. For vascular lesions including PVTT, the minimal CTV will be the vascular GTV without expansion; limited CTV expansion to adjacent regions considered at high risk for microscopic disease may be permitted when clinically indicated. For extrahepatic oligometastatic lesions, target delineation and any CTV expansion will follow site-specific SBRT contouring principles according to lesion location. Planning target volume will be generated from each CTV to account for setup uncertainty and internal organ motion, with margins individualized according to lesion site, motion assessment, immobilization, image guidance, and reproducibility under protocol-specified SBRT procedures. The total prescription dose in this study will range from 25 to 40 Gy in 5 fractions and will be individualized according to composite dosimetry, target location, underlying liver reserve, and proximity of adjacent luminal GI structures. For liver-directed targets, dose selection will be guided by the volume of uninvolved liver spared and by mean liver dose to the liver minus all GTVs, consistent with prospective individualized liver SBRT experience and contemporary external beam radiation therapy guidance for primary liver cancers.26,27 Within this protocol-defined dose range, the highest feasible prescription dose should be used while maintaining all protocol-specified normal tissue constraints. For 5-fraction liver-directed SBRT plans, the OAR planning framework is adapted from NRG/RTOG 1112. 13 For 5-fraction plans, mandatory constraints will include maximum dose to 0.5 cc of esophagus ⩽32 Gy, stomach ⩽30 Gy, duodenum ⩽30 Gy, small bowel ⩽30 Gy, large bowel ⩽32 Gy, spinal cord planning-risk volume ⩽25 Gy, and bilateral kidney mean dose ⩽10 Gy. Additional planning goals, when relevant, will include liver minus all GTVs > 700 cc with V10Gy < 70%, skin D0.5cc < 32 Gy, chest wall D0.5cc < 50 Gy, gallbladder D0.5cc < 55 Gy, and common bile duct D0.5cc < 50 Gy. For extrahepatic targets, additional site-specific OAR constraints will be applied according to lesion location and composite dosimetry. Treatment modification and toxicity management Protocol treatment may be delayed, temporarily withheld, omitted, or permanently discontinued according to toxicity type, severity, recovery, and attribution. Toxicity attribution will be determined by the multidisciplinary team on the basis of clinical course, laboratory abnormalities, imaging findings, and alternative explanations, including tumor progression, infection, viral hepatitis reactivation, biliary obstruction, and hepatic decompensation. 1. Immune-related toxicities: 1. Immune-related toxicities: ● Suspected immune-related adverse events (irAEs), including pneumonitis, colitis, hepatitis, endocrinopathy, and nephritis, will prompt interruption of iparomlimab/tuvonralimab and appropriate diagnostic evaluation to exclude competing causes. ● Suspected immune-related adverse events (irAEs), including pneumonitis, colitis, hepatitis, endocrinopathy, and nephritis, will prompt interruption of iparomlimab/tuvonralimab and appropriate diagnostic evaluation to exclude competing causes. ● For clinically significant immune-related toxicities, management will follow contemporary ICI guidance, including corticosteroids when indicated and organ-specific supportive care with specialist consultation as appropriate. ● For clinically significant immune-related toxicities, management will follow contemporary ICI guidance, including corticosteroids when indicated and organ-specific supportive care with specialist consultation as appropriate. ● Severe, life-threatening, recurrent, or steroid-refractory irAEs will require permanent discontinuation. ● Severe, life-threatening, recurrent, or steroid-refractory irAEs will require permanent discontinuation. ● Endocrine toxicities will be managed primarily with hormone replacement and temporary interruption when required; treatment may resume once the patient is clinically stable on appropriate replacement therapy. ● Endocrine toxicities will be managed primarily with hormone replacement and temporary interruption when required; treatment may resume once the patient is clinically stable on appropriate replacement therapy. 2. Bevacizumab-related toxicities: 2. Bevacizumab-related toxicities: ● Bevacizumab will be withheld for severe hypertension not adequately controlled with medical management, clinically significant proteinuria, or unresolved mucosal or GI toxicity, and may be resumed after adequate recovery according to protocol criteria. ● Bevacizumab will be withheld for severe hypertension not adequately controlled with medical management, clinically significant proteinuria, or unresolved mucosal or GI toxicity, and may be resumed after adequate recovery according to protocol criteria. ● Bevacizumab will be permanently discontinued for grade 3–4 bleeding, GI perforation or fistula, hypertensive crisis or hypertensive encephalopathy, nephrotic syndrome, severe arterial thromboembolic events, or grade 4 venous thromboembolism. ● Bevacizumab will be permanently discontinued for grade 3–4 bleeding, GI perforation or fistula, hypertensive crisis or hypertensive encephalopathy, nephrotic syndrome, severe arterial thromboembolic events, or grade 4 venous thromboembolism. 3. HAIC-related toxicities: 3. HAIC-related toxicities: ● HAIC administration may be delayed, omitted, or modified in the presence of unresolved hematologic toxicity, hepatic dysfunction, clinically relevant oxaliplatin-related neuropathy, or catheter-related complications. ● HAIC administration may be delayed, omitted, or modified in the presence of unresolved hematologic toxicity, hepatic dysfunction, clinically relevant oxaliplatin-related neuropathy, or catheter-related complications. ● Patients with myelosuppression, worsening liver function, infection, thrombosis, bleeding related to catheterization, or other procedure-related complications will receive supportive treatment and be reassessed before subsequent HAIC exposure. ● Patients with myelosuppression, worsening liver function, infection, thrombosis, bleeding related to catheterization, or other procedure-related complications will receive supportive treatment and be reassessed before subsequent HAIC exposure. ● Subsequent HAIC cycles may proceed only after recovery to protocol-defined retreatment criteria and confirmation that further intra-arterial therapy remains clinically appropriate. ● Subsequent HAIC cycles may proceed only after recovery to protocol-defined retreatment criteria and confirmation that further intra-arterial therapy remains clinically appropriate. 4. SBRT-related toxicities: 4. SBRT-related toxicities: ● SBRT will be deferred in patients with unresolved clinically significant hepatic decompensation, active uncontrolled infection, active GI ulceration or bleeding, or failure to meet protocol-defined liver reserve and OAR requirements. ● SBRT will be deferred in patients with unresolved clinically significant hepatic decompensation, active uncontrolled infection, active GI ulceration or bleeding, or failure to meet protocol-defined liver reserve and OAR requirements. ● Patients will be monitored closely for radiation-induced liver disease (RILD) and GI toxicity after SBRT, particularly during the first 3 months after irradiation. ● Patients will be monitored closely for radiation-induced liver disease (RILD) and GI toxicity after SBRT, particularly during the first 3 months after irradiation. Viral hepatitis management For patients with active HBV infection, protocol-defined baseline virologic criteria must be met before study treatment, and antiviral therapy with entecavir should be initiated before study treatment and continued throughout treatment and for at least 6 months after completion of study treatment. HBsAg-positive patients will undergo regular monitoring of HBV DNA levels during treatment, with viral load testing recommended every 1–2 months during this period. Patients who test positive for hepatitis C antibody will be assessed for HCV RNA; if positive, protocol-defined baseline HCV RNA criteria must be met before study treatment, and antiviral therapy may be considered according to clinical judgment. Retreatment criteria for subsequent cycles Prior to initiation of each subsequent treatment cycle, patients will be reassessed and must meet all of the following criteria: Absence of a second primary malignancy. Absence of a second primary malignancy. ECOG performance status ⩽2. ECOG performance status ⩽2. Hematologic toxicities ⩽Grade 2, with PLT ⩾30 × 109/L or recovery to baseline levels prior to treatment. Hematologic toxicities ⩽Grade 2, with PLT ⩾30 × 109/L or recovery to baseline levels prior to treatment. ALT ⩽ 3× ULN, AST ⩽ 3×ULN, TBiL ⩽ 2×ULN, and serum creatinine ⩽ 1.5×ULN. ALT ⩽ 3× ULN, AST ⩽ 3×ULN, TBiL ⩽ 2×ULN, and serum creatinine ⩽ 1.5×ULN. No evidence of disease progression. No evidence of disease progression. Patients who fail to meet criteria (1) or (5) will be withdrawn from the study. Those who do not meet criteria (2), (3), or (4) may receive appropriate supportive care and resume treatment once recovery is achieved. In cases of disease recurrence or progression, subsequent therapeutic strategies will be determined based on multidisciplinary team recommendations. Biospecimen collection for exploratory biomarker analyses For exploratory translational analyses, available archival tumor tissue or fresh pretreatment biopsy specimens will be used for assessment of PD-L1 expression and TMB at baseline. For blood-based exploratory analyses, whole blood and/or peripheral blood mononuclear cell samples, together with matched serum and plasma samples, will be collected at baseline and on day 1 before HAIC initiation of each HAIC-containing 21-day cycle (up to four cycles). An additional matched blood sample will be collected at 4 (±1) weeks after completion of SBRT in patients who proceed to SBRT. In patients who do not proceed to SBRT, a matched post-induction blood sample will be collected at the first follow-up imaging assessment approximately 1 month after the cycle 4 imaging assessment. Samples will be collected, processed, and stored according to standardized study procedures at the study center. Evaluation of therapeutic efficacy and follow-up For patients who undergo SBRT, the first post-SBRT imaging assessment will be performed 1 month after completion of SBRT. For patients who achieve CR, the first follow-up imaging assessment will be performed approximately 1 month after the cycle 4 imaging assessment. Thereafter, imaging evaluations will be performed every 2 months (±7 days) until disease progression, initiation of a new anticancer therapy, withdrawal of informed consent, death, or study termination. Tumor response will be assessed according to the RECIST 1.1, recording CR, PR, SD, PD, and derived ORR, DCR, and LCR. For patients who discontinue study treatment for reasons other than disease progression, an imaging assessment will be conducted within 1 month after treatment discontinuation, and follow-up will continue as scheduled thereafter. Safety evaluation AEs will be monitored continuously from informed consent through the end of study follow-up and graded per NCI CTCAE v5.0. A safety follow-up assessment will be performed 30 days (±7 days) after the last study dose (in person or by telephone) to confirm acute AEs. Thereafter, participants will enter survival/late-toxicity follow-up every 3 months (±7 days) for up to 24 months, during which late AEs will be assessed and recorded. If a new anticancer therapy is initiated after the last SBRT fraction, only serious AEs considered related to the study drugs will be collected thereafter. Quality of life assessment In addition to evaluating treatment efficacy in patients with advanced HCC, health-related quality of life represents a critical outcome of this study. Quality of life will be assessed using two validated instruments: EORTC QLQ-C30 and the HCC-specific module QLQ-HCC18 to provide a comprehensive evaluation of functional status and symptom burden. Assessments will be performed before initiation of the study treatment and at 3, 6, 12 months after treatment initiation. These evaluations will allow longitudinal assessment of within-cohort changes over time. Statistical analysis The primary endpoint is PFS. For sample-size determination, a historical benchmark median PFS of M0 = 6.0 months and an alternative median PFS of M1 = 9.0 months were prespecified. Under an exponential assumption, this corresponds to a hazard ratio of approximately 0.67. The choice of M0 = 6.0 months was anchored primarily to contemporary first-line immunotherapy-based data in advanced HCC, particularly the updated IMbrave150 analysis, in which median PFS with atezolizumab plus bevacizumab was 6.9 months overall and 5.4 months in the exploratory Vp4 subgroup. Accordingly, M0 = 6.0 months was considered a conservative and clinically meaningful null benchmark for this single-arm phase II study.28,29 The primary hypothesis will be evaluated with a one-sample, one-sided log-rank test (α = 0.05) against the survival distribution implied by M0. Patients will be accrued over 24 months, (accrual period, Ta = 24 months), followed by an additional 12 months of cohort-level follow-up after the last patient is enrolled (additional follow-up period, Tf = 12 months). Under this design, 48 evaluable patients are required; assuming ~10% annual attrition, the planned sample size is 54, yielding ~80% power. Time-to-event endpoints (PFS, OS) will be summarized by Kaplan–Meier estimates with medians and 95% CIs. ORR and DCR will be summarized per RECIST 1.1 with exact binomial 95% CIs. Continuous variables will be summarized as mean ± standard deviation or median (IQR/range), and categorical variables as counts and percentages. Unless otherwise specified, secondary/exploratory analyses will be two-sided at α = 0.05 without multiplicity adjustment. Analyses will be performed using R software, version 4.0.2 or higher (R Foundation for Statistical Computing, Vienna, Austria). Interim futility analysis A predefined interim analysis will be conducted after the first 15 evaluable patients have completed the imaging assessment planned after completion of cycle 4 according to RECIST version 1.1. If fewer than 3 of these 15 evaluable patients achieve an objective response (CR or PR), enrollment will be suspended, and a formal futility review will be performed by the SRC/DSMB; if the futility boundary is confirmed, the study will be terminated for futility. If at least three objective responses are observed and no major safety concerns are identified, accrual will continue to the planned sample size. Data collection and management All patient information will be kept strictly confidential, and data ownership will remain with Shandong Cancer Hospital. Disclosure to any third party not involved in this study is strictly prohibited. All clinical study documents, including case report forms, will be archived at the study center in compliance with Good Clinical Practice (GCP) requirements and retained for at least 5 years after study completion. Appropriate measures will be implemented to ensure data security, integrity, and traceability throughout the study. Discussion Locoregional–systemic combinations have recently reshaped the treatment landscape for unresectable, non-metastatic HCC.11,12,30 TACE has long been the standard of care in this setting, and the addition of immunotherapy and antiangiogenic agents has operationalized a “locoregional plus systemic” paradigm.10,30,31 In particular, the phase III EMERALD-1 trial, evaluating durvalumab plus bevacizumab in combination with TACE, and the LEAP-012 trial, investigating pembrolizumab plus lenvatinib with TACE, both demonstrated significantly improved PFS compared with TACE alone (median PFS approximately 15.0 vs 8.2 months in EMERALD-1 and 14.6 vs 10.0 months in LEAP-012), with concordant increases in ORRs, supporting guideline endorsement of TACE–immunotherapy/anti-VEGF combinations as preferred options for unresectable, non-metastatic HCC.9,11,12 However, patients with BCLC stage C HCC complicated by PVTT and/or extrahepatic oligometastases were under-represented or excluded from these trials. In this population, TACE is often technically challenging or contraindicated because of compromised portal flow and extensive intrahepatic tumor burden.9,10 As a result, it remains unclear how to translate the success of TACE-based locoregional–systemic strategies into a durable locoregional control pathway for this high-risk subset. Against this backdrop, our study focuses on this subset of patients with BCLC stage C disease, in whom resection is rarely feasible and overall outcomes remain poor despite contemporary first-line immunotherapy-based regimens.3,29,32 Accordingly, we designed a sequential, response-adapted multimodal strategy integrating HAIC, bevacizumab plus iparomlimab/tuvonralimab, and consolidative SBRT for this high-risk population. Within this sequence, HAIC is delivered first to achieve early intrahepatic cytoreduction and may also help biologically prime subsequent immunotherapy, as locoregional therapy can promote tumor antigen release and oxaliplatin has been shown to induce immunogenic cell death and enhance sensitivity to ICIs in HCC models.33,34 PFS was chosen as the primary endpoint because it more comprehensively captures the expected benefit of this sequential multimodal strategy than tumor response alone, incorporating not only tumor shrinkage but also durable disease control and delayed progression in this high-risk advanced HCC population. Furthermore, as this is a single-arm exploratory phase II study primarily powered for PFS, interpretation of the secondary OS analysis will remain limited by the planned sample size and follow-up duration. If this regimen demonstrates acceptable safety and encouraging efficacy, subsequent randomized phase III evaluation should formally assess OS as a primary endpoint, or consider OS as a co-primary endpoint depending on the final confirmatory design. The principal safety concern with multimodal therapy is additive toxicity, including myelosuppression and hepatic function fluctuation from HAIC, antiangiogenic–related bleeding/proteinuria, irAEs, and SBRT-associated risks such as RILD and GI injury.13,19,22,28 Nevertheless, accumulating data from adjacent settings support the feasibility of combining these components. In NRG/RTOG 1112, incorporation of SBRT for locally advanced HCC did not increase the incidence of grade ⩾3 treatment-related AEs compared with sorafenib alone (42% vs 47%), indicating acceptable combined toxicity. 13 The randomized, open-label phase II/III DUBHE-H-308 trial similarly reported a manageable safety profile without new signals for iparomlimab and tuvonralimab (QL1706) with bevacizumab and/or chemotherapy in first-line treatment of advanced HCC, supporting the tolerability of dual ICI plus anti-VEGF therapy. 20 Multiple reports of HAIC-FOLFOX combined with immunotherapy and/or anti-VEGF agents (e.g., atezolizumab plus bevacizumab) also describe manageable AEs,23,35,36 and HAIC combined with RT in PVTT-predominant cohorts has not been associated with excess severe toxicity.37–39 However, we recognize that this exact combination and sequence has not been extensively evaluated as an integrated regimen. Accordingly, our study is explicitly designed to limit cumulative toxicity while prospectively characterizing the overall safety profile. Risk-mitigation measures include prespecified eligibility thresholds, dose-modification and treatment-interruption rules, and intensified monitoring focused on hepatic decompensation and GI events, immune-related AEs, bevacizumab-associated complications, and RILD. Importantly, this stepwise, protocol-defined treatment sequence is intended to phase and compartmentalize toxicities over time, allowing early identification and triage of AEs before delivery of ablative-dose SBRT. Accordingly, enrollment was restricted to patients with Child–Pugh class A liver function to enhance safety and reduce baseline hepatic heterogeneity in this complex multimodal regimen. Although this restriction necessarily limits the generalizability of the study to patients with preserved hepatic function, we consider it appropriate given the overlapping hepatic risks associated with HAIC, bevacizumab-based immunotherapy, and SBRT. In addition, to further strengthen patient safety before full accrual expansion, the protocol also incorporates a preliminary safety/feasibility run-in cohort. Our study was intentionally designed as an exploratory, single-center, single-arm phase II trial in a high-risk population with BCLC stage C HCC and PVTT and/or extrahepatic oligometastases. The single-center design may limit the external generalizability of the findings, and the lack of a concurrent control arm limits direct causal inference. Accordingly, any encouraging safety and efficacy signals generated by this study will require validation in future multicenter randomized controlled trials. In conclusion, by prospectively evaluating a sequential regimen of bevacizumab and iparomlimab/tuvonralimab combined with HAIC followed by SBRT under strict liver dose-volume histogram constraints, the present study aims to characterize the safety profile, feasibility, and preliminary efficacy of an alternative locoregional–systemic pathway for patients with BCLC stage C HCC complicated by PVTT and/or extrahepatic oligometastases. If the regimen proves tolerable and shows encouraging signals in terms of tumor response, LCR and PFS, it could help fill the current therapeutic gap for this high-risk population and inform the design of future randomized trials and more refined, stage- and anatomy-adapted treatment algorithms for advanced HCC in the era of immunotherapy. Supplemental Material sj-pdf-1-tam-10.1177_17588359261470693 – Supplemental material for Bevacizumab plus iparomlimab/tuvonralimab with hepatic artery infusion chemotherapy followed by stereotactic body radiotherapy in patients with BCLC stage C hepatocellular carcinoma with thrombus and/or extrahepatic oligometastases (BITS-TO-HCC): study protocol of a prospective, single-center, single-arm, phase II study Supplemental material, sj-pdf-1-tam-10.1177_17588359261470693 for Bevacizumab plus iparomlimab/tuvonralimab with hepatic artery infusion chemotherapy followed by stereotactic body radiotherapy in patients with BCLC stage C hepatocellular carcinoma with thrombus and/or extrahepatic oligometastases (BITS-TO-HCC): study protocol of a prospective, single-center, single-arm, phase II study by Yuxin Liu, Haohua Wang, Kunli Zhu, Shumei Jiang, Fang Shi, Rui Feng, Xue Dou, Lei Xu, Zhe Gong, Shuai Wang, Chen Wang, Po Wang, Xiang Zhang and Jinbo Yue in Therapeutic Advances in Medical Oncology Acknowledgments We would like to thank all the patients who participated in this study. Footnotes ORCID iDs: Yuxin Liu https://orcid.org/0000-0001-6577-6019 Lei Xu https://orcid.org/0000-0002-4629-7415 Chen Wang https://orcid.org/0009-0002-4451-0822 Jinbo Yue https://orcid.org/0000-0001-5242-6554 Supplemental material: Supplemental material for this article is available online. Contributor Information Yuxin Liu, Shandong University Cancer Center, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China; Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China. Haohua Wang, Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China; Department of Oncology, Renmin Hospital of Wuhan University, Wuhan, Hubei, China. Kunli Zhu, Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China. Shumei Jiang, Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China. Fang Shi, Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China. Rui Feng, Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China. Xue Dou, Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China. Lei Xu, Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China. Zhe Gong, Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China. Shuai Wang, Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China. Chen Wang, Shandong University Cancer Center, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China; Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China. Po Wang, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China. Xiang Zhang, Shandong University Cancer Center, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China; Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, No. 440, Jiyan Road, Huaiyin District, Jinan, Shandong 250117, China. Jinbo Yue, Shandong University Cancer Center, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China; Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, No. 440, Jiyan Road, Huaiyin District, Jinan, Shandong 250117, China. Declarations Ethics approval and consent to participate: The final protocol (Grant No. SDZLEC2025-152-04) was approved by the Ethics Committee of the Affiliated Cancer Hospital of Shandong First Medical University, Jinan, Shandong Province, China, on November 6, 2025, in accordance with the Declaration of Helsinki and GCP principles. Formal approval is required for any change to the protocol that affects the conduct, patient benefit or safety of the trial. The trial will adhere to local regulations. Consent to participate: Patients will provide written informed consent after receiving a thorough explanation of the rationale, benefits and potential side effects. Consent for publication: Not applicable. Author contributions: Yuxin Liu: Writing – original draft; Writing – review & editing. Haohua Wang: Writing – original draft; Writing – review & editing. Kunli Zhu: Resources. Shumei Jiang: Resources. Fang Shi: Resources. Rui Feng: Resources. Xue Dou: Resources. Lei Xu: Resources. Zhe Gong: Resources. Shuai Wang: Resources. Chen Wang: Resources. Po Wang: Resources. Xiang Zhang: Conceptualization; Supervision. Jinbo Yue: Conceptualization; Supervision. Funding: The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the following grants: National Natural Science Foundation of China (Grant No. 82272753), Noncommunicable Chronic Diseases-National Science and Technology Major Project (2023ZD0501600). The funders were not involved in the design of the study; the data collection, analysis, or interpretation; or the writing of the manuscript. The authors declare that there is no conflict of interest. Availability of data and materials: The datasets used and/or analyzed during the current study were available from the corresponding author upon reasonable request.* References Associated Data Supplementary Materials sj-pdf-1-tam-10.1177_17588359261470693 – Supplemental material for Bevacizumab plus iparomlimab/tuvonralimab with hepatic artery infusion chemotherapy followed by stereotactic body radiotherapy in patients with BCLC stage C hepatocellular carcinoma with thrombus and/or extrahepatic oligometastases (BITS-TO-HCC): study protocol of a prospective, single-center, single-arm, phase II study Supplemental material, sj-pdf-1-tam-10.1177_17588359261470693 for Bevacizumab plus iparomlimab/tuvonralimab with hepatic artery infusion chemotherapy followed by stereotactic body radiotherapy in patients with BCLC stage C hepatocellular carcinoma with thrombus and/or extrahepatic oligometastases (BITS-TO-HCC): study protocol of a prospective, single-center, single-arm, phase II study by Yuxin Liu, Haohua Wang, Kunli Zhu, Shumei Jiang, Fang Shi, Rui Feng, Xue Dou, Lei Xu, Zhe Gong, Shuai Wang, Chen Wang, Po Wang, Xiang Zhang and Jinbo Yue in Therapeutic Advances in Medical Oncology